Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07768176
PHASE1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PTT-121

Sponsor: Pyrotech Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase I, single-center, randomized, double-blind, placebo-controlled SAD/MAD study to evaluate safety, tolerability, and PK of Intravenously Administered PTT-121 in healthy Chinese adults.

Official title: A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PTT-121 After Single and Multiple Ascending Doses in Healthy Chinese Subjects

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

84

Start Date

2026-08-31

Completion Date

2028-02-28

Last Updated

2026-08-17

Healthy Volunteers

Yes

Interventions

DRUG

PTT-121

PTT-121 will be administered intravenously

DRUG

PTT-121 placebo

Matching placebo identical to PTT-121 formulation but without the active pharmaceutical ingredient

Locations (1)

Peking University Third Hospital

Beijing, Beijing Municipality, China